Emmanuelle Clappier

Paris, 75010, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 115 publications

Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.

Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.

Journal: Science translational medicine
Published: July 08, 2026

Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.

Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.

Journal: Leukemia
Published: April 12, 2026

Predisposition to ALL and Solid Tumors Rather Than Bone Marrow Failure in FANCM-Associated Fanconi Anemia.

Predisposition to ALL and Solid Tumors Rather Than Bone Marrow Failure in FANCM-Associated Fanconi Anemia.

Journal: JCO precision oncology
Published: March 25, 2026

Persistent BCR::ABL1-positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome-positive ALL.

Persistent BCR::ABL1-positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome-positive ALL.

Journal: HemaSphere
Published: March 11, 2026

CEBP and ZEB2 alterations define three distinct subtypes of B-cell acute lymphoblastic leukemia.

CEBP and ZEB2 alterations define three distinct subtypes of B-cell acute lymphoblastic leukemia.

Journal: HemaSphere
Published: February 01, 2026

Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study.

Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study.

Journal: Blood
Published: January 20, 2026

Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.

Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.

Journal: Blood
Published: January 20, 2026

Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.

Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.

Journal: Leukemia
Published: October 15, 2025

Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.

Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.

Journal: British journal of haematology
Published: September 17, 2025

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.

Journal: Leukemia
Published: August 25, 2025

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

Journal: Blood
Published: August 14, 2025

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

Journal: Blood
Published: August 14, 2025
Showing 1-12 of 115

Last Updated: 09/26/2026